Allurion Technologies Inc. (NYSE:ALUR), a leader in innovative weight loss solutions, is set to resume patient treatments in ...

NATICK, Mass., May 29, 2025--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that Dr. Shantanu Gaur ...

Allurion Technologies Inc. (NYSE:ALUR) Q1 2025 Earnings Call Transcript May 14, 2025 Allurion Technologies Inc. beats earnings expectations. Reported EPS is $0.43, expectations were $-1.53.

Good morning, and thank you all for joining us. Earlier today, Allurion Technologies Inc. issued a press release announcing financial results for the quarter ended December 31st, 2024 and provided ...

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today ...

Allurion Technologies Inc. (NYSE:ALUR – Get Free Report) was the recipient of a large decline in short interest during the month of April.As of April 15th, there was short interest totalling ...

Four abstracts presented at the European Congress on Obesity Data indicate potential synergies of Allurion's swallowable Procedureless TM intragastric balloon (the "Allurion Balloon") and Virtual ...

ANSM, the French regulatory authority, clears Allurion to resume sales of the ... and GLP-1s to prevent muscle loss Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a ...

Allurion Technologies, Inc. develops treatments for obesity. The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, a swallowable, procedure-less gastric ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...